Last updated on October 2018

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes


Brief description of study

This is an open-label Phase IIIb study of dabrafenib in combination with trametinib in the adjuvant treatment of melanoma after complete resection to evaluate the impact on pyrexia related outcomes of an adapted pyrexia AE-management algorithm, as well as safety, efficacy and health-related outcomes. ' Approximately 600 subjects will be enrolled to receive dabrafenib (150 mg BID) and trametinib (2 mg once daily) combination therapy for 12 months. At enrollment, subjects will be instructed on the pyrexia management algorithm.

This study consists of two Periods for Enrolled subjects:

  • Treatment Period - subjects will receive up to 12 months of treatment.
  • Follow-up Period - subjects will be followed through 24 months from their first dose date for relapse, and through end of study for overall survival. Follow-up will start once treatment is complete or is prematurely discontinued and continue through the end of the study, regardless of disease recurrence.

Clinical Study Identifier: NCT03551626

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Tampere, Finland
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Jerusalem, Israel
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Bristol, United Kingdom
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Northwood, United Kingdom
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Cambridge, United Kingdom
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Hradec Kralove, Czechia
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Milano, Italy
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Boulogne Billancourt, France
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Toulouse Cedex 9, France
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Inverness, Invernesshire, United Kingdom
  Connect »